IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 334 filers reported holding IONIS PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 0.71 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $51,756 | -48.9% | 1,141 | -50.6% | 0.00% | 0.0% |
| Q2 2023 | $101,223 | +10.3% | 2,310 | +17.3% | 0.00% | -50.0% |
| Q1 2023 | $91,774 | +39288.0% | 1,969 | -59.3% | 0.00% | -33.3% |
| Q4 2022 | $233 | -99.9% | 4,838 | -16.4% | 0.01% | -14.3% |
| Q3 2022 | $279,000 | 0.0% | 5,789 | 0.0% | 0.01% | -22.2% |
| Q2 2022 | $279,000 | -37.3% | 5,789 | -36.8% | 0.01% | +50.0% |
| Q1 2022 | $445,000 | +378.5% | 9,162 | +242.8% | 0.01% | +200.0% |
| Q4 2021 | $93,000 | +40.9% | 2,673 | +55.4% | 0.00% | +100.0% |
| Q3 2021 | $66,000 | +46.7% | 1,720 | +45.9% | 0.00% | 0.0% |
| Q2 2021 | $45,000 | +246.2% | 1,179 | +295.6% | 0.00% | – |
| Q1 2021 | $13,000 | -38.1% | 298 | -21.8% | 0.00% | -100.0% |
| Q4 2020 | $21,000 | -51.2% | 381 | -57.6% | 0.00% | -66.7% |
| Q3 2020 | $43,000 | -34.8% | 899 | -18.7% | 0.00% | -40.0% |
| Q2 2020 | $66,000 | +17.9% | 1,106 | -0.7% | 0.01% | -16.7% |
| Q1 2020 | $56,000 | -39.1% | 1,114 | -27.1% | 0.01% | -14.3% |
| Q4 2019 | $92,000 | -52.1% | 1,529 | -52.7% | 0.01% | -46.2% |
| Q3 2019 | $192,000 | +6300.0% | 3,232 | +7980.0% | 0.01% | – |
| Q1 2019 | $3,000 | -93.8% | 40 | -95.7% | 0.00% | -100.0% |
| Q4 2018 | $48,000 | -7.7% | 929 | -7.5% | 0.00% | +50.0% |
| Q3 2018 | $52,000 | -49.5% | 1,004 | -59.4% | 0.00% | -50.0% |
| Q2 2018 | $103,000 | -39.8% | 2,472 | -27.5% | 0.00% | -50.0% |
| Q1 2018 | $171,000 | 0.0% | 3,408 | 0.0% | 0.01% | 0.0% |
| Q4 2017 | $171,000 | -34.7% | 3,408 | -34.0% | 0.01% | -20.0% |
| Q3 2017 | $262,000 | -9.3% | 5,167 | -9.0% | 0.01% | -16.7% |
| Q2 2017 | $289,000 | +9.9% | 5,680 | -13.3% | 0.01% | +9.1% |
| Q1 2017 | $263,000 | -39.1% | 6,551 | -27.5% | 0.01% | -47.6% |
| Q4 2016 | $432,000 | +41.6% | 9,034 | +8.7% | 0.02% | +31.2% |
| Q3 2016 | $305,000 | +84.8% | 8,313 | +17.0% | 0.02% | +77.8% |
| Q2 2016 | $165,000 | +5400.0% | 7,106 | +17665.0% | 0.01% | – |
| Q1 2016 | $3,000 | -99.4% | 40 | -99.5% | 0.00% | -100.0% |
| Q4 2015 | $501,000 | – | 8,085 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bellevue Group AG | 9,930,245 | $396,117,000 | 3.87% |
| Sicart Associates LLC | 368,409 | $14,696,000 | 3.50% |
| Camber Capital Management LP | 2,000,000 | $79,780,000 | 2.69% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 181,781 | $7,251,000 | 1.91% |
| SECTOR GAMMA AS | 263,488 | $10,511,000 | 1.86% |
| Parkman Healthcare Partners LLC | 136,380 | $5,440,000 | 1.19% |
| Eversept Partners, LP | 442,000 | $17,631,380 | 1.18% |
| Affinity Asset Advisors, LLC | 75,000 | $2,992,000 | 1.07% |
| TANAKA CAPITAL MANAGEMENT INC | 16,661 | $665,000 | 0.90% |
| Sonora Investment Management, LLC | 168,665 | $6,728,000 | 0.88% |